Advanced Enzyme Technologies has announced its financial performance for the quarter and fiscal year ended March 31, 2026. The company reported record-breaking revenue of INR 7,458 million for the full year, a 17% YoY increase. Operating margins remained strong at 31%, with the company achieving INR 453 million in profit after tax for the final quarter, showcasing a 69% year-on-year growth, driven by strategic product mix and operational efficiencies across all business divisions.
Record Annual Performance
The company achieved its highest-ever quarterly and annual revenue for the fiscal year ended March 31, 2026. Quarterly revenue reached INR 2,034 million, reflecting a robust 22% year-on-year growth. Operating profitability remained high, with an EBITDA of INR 632 million for the quarter, registering a 39% year-on-year growth. The annual profit after tax grew by 30%, underscoring the success of the company’s long-term business strategy.
Segmental Highlights
Human Healthcare continues to be the flagship division, contributing 63% of total revenue with 15% year-to-date growth. The Animal Healthcare segment reported a 19% year-on-year revenue increase, supported by strong performance in Asian markets. Additionally, the Specialized Manufacturing segment grew by 23% year-to-date, reflecting the successful diversification of the product portfolio.
Strategic Outlook and Innovation
Management emphasized that the business is pivoting toward high-growth areas, including protein and peptide enzymes. The company is investing significantly in R&D, with a new research facility in Nashik expected to be fully operational by the second half of the fiscal year. This expansion is designed to enhance the innovation pipeline and support long-term sustainable growth while navigating global supply chain complexities and inflationary pressures.
Operational Strategy
Despite global economic challenges, the company remains focused on customer retention and increasing market share in both developed and emerging regions. By optimizing capacity and prioritizing high-margin proprietary products, the management remains confident in maintaining steady momentum and delivering value to stakeholders in the upcoming fiscal year.
Source: BSE
